Skip to main content

Table 2 Association of placement of permanent vascular access with attribution of end-stage renal disease to systemic lupus erythematosus vs. other causes, among U.S. incident hemodialysis patients who started dialysis in 2010 with only a catheter in place

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Model No. (%) with permanent access placed within 1 year Hazard ratio (95 % CI) for placement of permanent vascular access, SLE-attributed vs. other ESRD
Unadjusted Adjusted for demographics Adjusted for demographics + clinical
All events     
 SLE-attributed ESRD 177 (46.1 %) 0.74 (0.64-0.86) 0.94 (0.81-1.09) 1.00 (0.86-1.17)
 Other ESRD 22,076 (54.5 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.001 <0.001 0.42 >0.9
All AVF placementsa     
 SLE-attributed ESRD 137 (35.7 %) 0.73 (0.62-0.87) 0.93 (0.79-1.11) 1.00 (0.84-1.18)
 Other ESRD 17,300 (42.7 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.006 <0.001 0.43 >0.9
All AVG placementsa     
 SLE-attributed ESRD 40 (10.4 %) 0.77 (0.56-1.05) 1.00 (0.73-1.38) 1.06 (0.77-1.47)
 Other ESRD 4,776 (11.8 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.41 0.10 >0.9 0.71
  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
  2. aTime-to-event analyses censored for placement of other type of access